Dr. Lin is the medical director of the Immune Effector Cell Program at Mayo Clinic in Rochester and oversees the practice of CAR-T and bispecific antibodies for patients with hematologic malignancy and solid tumors. Dr. Lin interfaces between MCCCC Research programs, disease groups and the Center for Regenerative Biotherapeutics (CRB) to develop strategies for highly innovative cancer therapeutics and therapeutic development.